Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy
Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficac...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Animals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2615/13/19/3002 |
| _version_ | 1797576292440211456 |
|---|---|
| author | Ana Rostaher Nina Maria Fischer Alessio Vigani Barbara Steblaj Franco Martini Salina Brem Claude Favrot Mitja Kosnik |
| author_facet | Ana Rostaher Nina Maria Fischer Alessio Vigani Barbara Steblaj Franco Martini Salina Brem Claude Favrot Mitja Kosnik |
| author_sort | Ana Rostaher |
| collection | DOAJ |
| description | Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 µg of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phases. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs. |
| first_indexed | 2024-03-10T21:50:09Z |
| format | Article |
| id | doaj.art-025b383a6c67488e9790a4bbee4850e1 |
| institution | Directory Open Access Journal |
| issn | 2076-2615 |
| language | English |
| last_indexed | 2024-03-10T21:50:09Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Animals |
| spelling | doaj.art-025b383a6c67488e9790a4bbee4850e12023-11-19T13:58:53ZengMDPI AGAnimals2076-26152023-09-011319300210.3390/ani13193002Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical EfficacyAna Rostaher0Nina Maria Fischer1Alessio Vigani2Barbara Steblaj3Franco Martini4Salina Brem5Claude Favrot6Mitja Kosnik7Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, SwitzerlandDermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, SwitzerlandDivision of Small Animal Emergency and Critical Care, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, SwitzerlandSection of Anaesthesiology, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, 8057 Zurich, SwitzerlandDermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, SwitzerlandDermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, SwitzerlandDermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, SwitzerlandDivision of Allergy, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, SloveniaHymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 µg of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phases. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.https://www.mdpi.com/2076-2615/13/19/3002anaphylaxisangioedemadogsHymenoptera allergyurticariavenom immunotherapy |
| spellingShingle | Ana Rostaher Nina Maria Fischer Alessio Vigani Barbara Steblaj Franco Martini Salina Brem Claude Favrot Mitja Kosnik Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy Animals anaphylaxis angioedema dogs Hymenoptera allergy urticaria venom immunotherapy |
| title | Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy |
| title_full | Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy |
| title_fullStr | Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy |
| title_full_unstemmed | Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy |
| title_short | Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy |
| title_sort | hymenoptera venom immunotherapy in dogs safety and clinical efficacy |
| topic | anaphylaxis angioedema dogs Hymenoptera allergy urticaria venom immunotherapy |
| url | https://www.mdpi.com/2076-2615/13/19/3002 |
| work_keys_str_mv | AT anarostaher hymenopteravenomimmunotherapyindogssafetyandclinicalefficacy AT ninamariafischer hymenopteravenomimmunotherapyindogssafetyandclinicalefficacy AT alessiovigani hymenopteravenomimmunotherapyindogssafetyandclinicalefficacy AT barbarasteblaj hymenopteravenomimmunotherapyindogssafetyandclinicalefficacy AT francomartini hymenopteravenomimmunotherapyindogssafetyandclinicalefficacy AT salinabrem hymenopteravenomimmunotherapyindogssafetyandclinicalefficacy AT claudefavrot hymenopteravenomimmunotherapyindogssafetyandclinicalefficacy AT mitjakosnik hymenopteravenomimmunotherapyindogssafetyandclinicalefficacy |